Company intelligence / Profile preview
Ollin Biosciences
Chicago, Illinois, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Ollin has acquired global (ex-China) rights to VBS-102, a first-in-class bispecific antibody targeting IGF-1R x TSHR for ophthalmic indications, currently in preclinical development with no disclosed human results; the company is funding academic research in glaucoma but has not announced internal clinical-stage data
- Therapeutic areas
- Ophthalmology
- Modalities
- Bispecific antibody
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
VelaVigo Cayman Limited (exclusive licensing of VBS-102, with milestone and royalty structure)
Beyond the preview
Go deeper on Ollin Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ollin Biosciences.